AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22212720 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy immunotherapy
Number of subjects: 20
Study 22212720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite immunotherapy
Number of subjects: 20
Study 22212720 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of conjunctival sensitivity
Number of subjects: 20
Study 22212720 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgG
Number of subjects: 20
Study 19059655 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise elevated exercise intensity in volunteers
Number of subjects: 63
Study 19059655 — intervention group
Group type: COMPARATOR
Intervention: DFA analysis in ACS patients
Number of subjects: 63
Study 18302834 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (H(1)-antihistamine)
Number of subjects: 20
Study 18302834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15747809 — intervention group
Group type: EXPERIMENTAL
Intervention: RME-Sz
Number of subjects: 44
Study 15747809 — intervention group
Group type: COMPARATOR
Intervention: RME-only
Number of subjects: 44
Study 12665084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus contingency management (CM)
Number of subjects: 193
Study 12665084 — intervention group
Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 193
Study 12665084 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 193
Study 10596569 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 104
Study 10596569 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 104
Study 9005798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin administered intravenously in a dose of 200 mg twice a day followed by oral use in the form of tablets in a dose of 200 mg twice a day for 5 to 6 days.
Number of subjects: 25
Study 9005798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin used orally in the form of tablets in a dose of 200 mg once a day in the morning for 5 to 7 days.
Number of subjects: 25
Study 9005798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin used in the same dosage but in combination with some other antibiotics.
Number of subjects: 25
Study 9005798 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics except for ofloxacin.
Number of subjects: 25
Study 1752022 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (HVT, 12.7 ml.kg‐1) ventilation
Number of subjects: 24
Study 1752022 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume (CVT, 7.5 ml.kg‐1) ventilation
Number of subjects: 24
Study 1752022 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflations (HI) of the lungs
Number of subjects: 24
Study 6753115 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/day for six weeks)
Number of subjects: 40
Study 6753115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30341408 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 400
Study 30341408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 28991600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective training during a 12-month clinical internship
Number of subjects: 157
Study 28991600 — intervention group
Group type: COMPARATOR
Intervention: Control group with reflective diaries but no formal training
Number of subjects: 157
Study 26852726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solithromycin (800 mg on day 1, 400 mg on days 2-5, placebo on days 6-7)
Number of subjects: 860
Study 26852726 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg on days 1-7)
Number of subjects: 860
Study 26852726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solithromycin
Number of subjects: 860
Study 26852726 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin
Number of subjects: 860
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% CO2
Number of subjects: 20
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 CO2:argon
Number of subjects: 20
Study 24664567 — intervention group
Group type: COMPARATOR
Intervention: Control (ambient air)
Number of subjects: 20
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster flow rates
Number of subjects: 20
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower flow rates
Number of subjects: 20
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonate pigs
Number of subjects: 20
Study 24664567 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaned pigs
Number of subjects: 20
Study 22760574 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (SS; 4 h/night)
Number of subjects: 21
Study 22760574 — intervention group
Group type: COMPARATOR
Intervention: Long sleep (LS; 9 h/night)
Number of subjects: 21
Study 20929552 — intervention group
Group type: EXPERIMENTAL
Intervention: Labral repair
Number of subjects: 120
Study 20929552 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 120
Study 20929552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diagnostic arthroscopy)
Number of subjects: 120
Study 20929552 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 120
Study 17908897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless tibial fixation with hydroxyapatite
Number of subjects: 81
Study 17908897 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial fixation
Number of subjects: 81
Study 16208714 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Fr guiding catheter
Number of subjects: 414
Study 16208714 — intervention group
Group type: COMPARATOR
Intervention: 7 Fr guiding catheter
Number of subjects: 414
Study 11834844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 50
Study 11834844 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 50
Study 10445371 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (25, 50, and 75 mg)
Number of subjects: 14
Study 10445371 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 14
Study 10445371 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon and Triazolam
Number of subjects: 14
Study 10445371 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 14
Study 10445371 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 14
Study 10445371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1541953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 degrees rotation of the Cervex-Brush
Number of subjects: 516
Study 1541953 — intervention group
Group type: COMPARATOR
Intervention: 180 degrees rotation of the Cervex-Brush
Number of subjects: 516
Study 1541953 — intervention group
Group type: COMPARATOR
Intervention: 360 degrees rotation of the Cervex-Brush
Number of subjects: 516
Study 1541953 — intervention group
Group type: COMPARATOR
Intervention: 720 degrees rotation of the Cervex-Brush
Number of subjects: 516
Study 1541953 — intervention group
Group type: COMPARATOR
Intervention: 1080 degrees rotation of the Cervex-Brush
Number of subjects: 516
Study 1541953 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 516
Study 4040553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg IV, two hours before and 3, 6, 9, and 12 hours after chemotherapy)
Number of subjects: 64
Study 4040553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 4040553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone after crossover from placebo
Number of subjects: 64
Study 30928952 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped observation by a clinical child psychologist or child psychiatrist and a study nurse followed by interactive video guidance
Number of subjects: 0
Study 30928952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30928952 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped observation and interactive video guidance
Number of subjects: 0
Study 29746955 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenously daily
Number of subjects: 113
Study 29746955 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole suspension 400 mg orally twice daily
Number of subjects: 113
Study 29746955 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 113
Study 29746955 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole
Number of subjects: 113
Study 29746955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 113
Study 26953867 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game-based cognitive rehabilitation program
Number of subjects: 24
Study 26953867 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 24
Study 26953867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 24
Study 26953867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 26137843 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention (Som la Pera) involving 5 Adolescent Challenge Creators (ACCs) who received 4 hours of training and 24 sessions (1.5 hours each) over 2 academic years.
Number of subjects: 240
Study 26137843 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention (Som la Pera) involving 5 Adolescent Challenge Creators (ACCs).
Number of subjects: 240
Study 26137843 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention implemented.
Number of subjects: 240
Study 23516998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss goal among nonsmokers
Number of subjects: 1592
Study 23516998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss goal among former smokers
Number of subjects: 1592
Study 23516998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss goal among smokers
Number of subjects: 1592
Study 21518127 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU oxytocin dissolved in 30 mL saline (n=26)
Number of subjects: 78
Study 21518127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometrine 0.2 mg dissolved in 30 mL saline (n=27)
Number of subjects: 78
Study 21518127 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 µg dissolved in 30 mL saline (n=25)
Number of subjects: 78
Study 21518127 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 78
Study 18285698 — intervention group
Group type: COMPARATOR
Intervention: F8 HPS (low-flux) dialyzer (Group A)
Number of subjects: 40
Study 18285698 — intervention group
Group type: EXPERIMENTAL
Intervention: FX80 (high-flux) dialyzer (Group B)
Number of subjects: 40
Study 17086737 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of oral midazolam 20 minutes prior to dental treatment
Number of subjects: 40
Study 12964680 — intervention group
Group type: EXPERIMENTAL
Intervention: MPDS‐SL
Number of subjects: 20
Study 12964680 — intervention group
Group type: COMPARATOR
Intervention: Molloplast‐B
Number of subjects: 20
Study 10999232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 13
Study 10999232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms via Turbohaler)
Number of subjects: 15
Study 9624295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to budesonide)
Number of subjects: 15
Study 7937971 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute jumping (intervention group, n = 26)
Number of subjects: 43
Study 7937971 — intervention group
Group type: COMPARATOR
Intervention: Control group (not jumping, n = 17)
Number of subjects: 43
Study 3064641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime ethanol (2 ml/kg of 100 proof vodka mixed in orange juice)
Number of subjects: 6
Study 3064641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1-2 drops of vodka floated on top of the orange juice)
Number of subjects: 6
Study 29761006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate, 30 mg/kg as loading dose and then 4-8 mg/kg every 8 hr as maintenance regimen
Number of subjects: 110
Study 29761006 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin (IV PHT) 20 mg/kg as loading dose and then 1.5 mg/kg for 8 hr as maintenance therapy
Number of subjects: 110
Study 29761006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sodium valproate and phenytoin)
Number of subjects: 110
Study 28107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (stepdown and non-stepdown groups)
Number of subjects: 246
Study 28107596 — intervention group
Group type: COMPARATOR
Intervention: Preferred brand (control group)
Number of subjects: 246
Study 28107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stepdown RNC cigarette groups
Number of subjects: 246
Study 28107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from preferred to lowest RNC cigarettes
Number of subjects: 246
Study 28107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from highest to lowest RNC cigarettes
Number of subjects: 246
Study 28107596 — intervention group
Group type: EXPERIMENTAL
Intervention: More favorable initial taste ratings of study cigarettes
Number of subjects: 246
Study 25692315 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (B1)
Number of subjects: 50
Study 25692315 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (B2)
Number of subjects: 50
Study 25692315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iron and folic acid supplementation (B3)
Number of subjects: 50
Study 25692315 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplementation (B4)
Number of subjects: 50
Study 25692315 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pregnant healthy women)
Number of subjects: 50
Study 22963271 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic combination remedy dysto-loges S
Number of subjects: 40
Study 22963271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20636249 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief individual cognitive behavioral counseling comprising three weekly 1 hour sessions (n = 33)
Number of subjects: 67
Study 20636249 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 34)
Number of subjects: 67
Study 18829240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 25
Study 18829240 — intervention group
Group type: COMPARATOR
Intervention: Bare stent
Number of subjects: 25
Study 16606389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous lead removal using locking stylets and sheaths
Number of subjects: 53
Study 16606389 — intervention group
Group type: COMPARATOR
Intervention: Primary lead removal using sternotomy and extracorporeal circulation (ECC)
Number of subjects: 53
Study 16606389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous lead removal
Number of subjects: 53
Study 16606389 — intervention group
Group type: COMPARATOR
Intervention: Primary lead removal using ECC
Number of subjects: 53
Study 12538506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 13647
Study 12538506 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily)
Number of subjects: 13647
Study 12538506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13647
Study 10664941 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCyte PREP liquid‐based, thin‐layer preparation
Number of subjects: 0
Study 10664941 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap smear
Number of subjects: 0
Study 8793608 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole s.i.d. for 10 days and 20 mg nifedipine sustained release (SR) b.i.d. from day 6 to 10
Number of subjects: 24
Study 8793608 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nifedipine SR b.i.d. for 5 days (reference period)
Number of subjects: 24
Study 1503072 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 371
Study 1503072 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 371
Study 3930248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.5 mg sublingually
Number of subjects: 0
Study 3930248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30522768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (11% oxygen balanced in nitrogen)
Number of subjects: 8
Study 30522768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxemia (carbon monoxide plus normoxia)
Number of subjects: 8
Study 30522768 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (room air)
Number of subjects: 8
Study 28801149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60
Study 28801149 — intervention group
Group type: COMPARATOR
Intervention: Neutral hypnosis (placebo)
Number of subjects: 60
Study 27605491 — intervention group
Group type: EXPERIMENTAL
Intervention: LP 532-nm laser alone
Number of subjects: 22
Study 27605491 — intervention group
Group type: EXPERIMENTAL
Intervention: LP 532-nm laser in combination with LP 1064-nm laser
Number of subjects: 22
Study 24298995 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 339
Study 24298995 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 339
Study 22168810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236
Study 22168810 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study 20389213 — intervention group
Group type: EXPERIMENTAL
Intervention: House flap
Number of subjects: 60
Study 20389213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid flap
Number of subjects: 60
Study 20389213 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-V anoplasty
Number of subjects: 60
Study 17389658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once-weekly (QW)
Number of subjects: 356
Study 17389658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice-weekly (BIW)
Number of subjects: 356
Study 17389658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 16310609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU QD SC
Number of subjects: 129
Study 16310609 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU BID SC
Number of subjects: 129
Study 12171433 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of HCA for 5 days
Number of subjects: 0
Study 12171433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 0
Study 10615818 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission system (telematic data transmission)
Number of subjects: 17
Study 10615818 — intervention group
Group type: COMPARATOR
Intervention: Classical treatment
Number of subjects: 17
Study 7777424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI Endotak lead system
Number of subjects: 307
Study 2106732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (a cephalosporin with a long half-life)
Number of subjects: 0
Study 2106732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (a broad-spectrum ureidopenicillin)
Number of subjects: 0
Study 210379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-polymyxin irrigant administered through closed urinary catheters
Number of subjects: 187
Study 210379 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 187
Study 31400271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg initial dose and then 0.2 µg/kg/h for 10 minutes)
Number of subjects: 60
Study 31400271 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-Fentanyl (0.05 mg/kg fentanyl at a dose of 1 µg/kg for 10 minutes)
Number of subjects: 60
Study 29171646 — intervention group
Group type: EXPERIMENTAL
Intervention: slow rocuronium injection (0.6 mg/kg IV) with remifentanil
Number of subjects: 120
Study 29171646 — intervention group
Group type: EXPERIMENTAL
Intervention: fast rocuronium injection with remifentanil
Number of subjects: 120
Study 29171646 — intervention group
Group type: COMPARATOR
Intervention: slow rocuronium injection with saline
Number of subjects: 120
Study 29171646 — intervention group
Group type: COMPARATOR
Intervention: fast rocuronium injection with saline
Number of subjects: 120
Study 29171646 — intervention group
Group type: EXPERIMENTAL
Intervention: slow rocuronium injection with remifentanil
Number of subjects: 120
Study 24845600 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocortical Stimulation (ECS)
Number of subjects: 23
Study 24845600 — intervention group
Group type: EXPERIMENTAL
Intervention: high gamma electrocorticography (hgECoG)
Number of subjects: 23
Study 24845600 — intervention group
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging (fMRI)
Number of subjects: 23
Study 24845600 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgical outcomes
Number of subjects: 23
Study 23836616 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic smoking ascertainment and default provision of behavioural support and cessation pharmacotherapy during hospital stay; follow-up and referral to community services after discharge.
Number of subjects: 493
Study 23836616 — intervention group
Group type: COMPARATOR
Intervention: Usual care comprising cessation support delivered at the initiative and discretion of clinical staff.
Number of subjects: 493
Study 21745115 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 60